



	Questions : Lok Sabha




























Screen Reader Access
Skip to Main Content
Skip to Navigation



Text Size

                                A

                                A
A















हिन्दी मे








Parliament of India Lok Sabha House of the
                        People






* Special Characters not allowed












India Time 


Your Time 


                        Monday,
                        11 April 2022









HomeMembersSitting MembersMembers Home PageMembers' PortalContact DetailsMembers SearchStatistical AnalysisAttendance of MembersHandbook Members Since 1952Digitized Who's WhoOthers BusinessProvisional CalendarList of BusinessPapers to be LaidList of Private Members' BusinessBulletin-IDigitized Lok Sabha Bulletin Part IBulletin-IIStatement of WorkSpecial Mentions (ZERO HOUR)Resume of WorkDigitized Resume of Work done by Lok Sabha QuestionsHomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions DebatesIntroductionSynopsisUncorrected DebateText of DebateDigitized DebatesConstituent Assembly DebatesWit And HumourDebate SearchHindi FontsDisclaimer Papers LaidPapers Laid on the Table of the House LegislationIntroduction(How Bill Becomes Act)Bills IntroducedBills PassedBills PendingBills AssentedBills LapsedBills WithdrawnBills NegativedBills Search Disclaimer CommitteesIntroductionChairpersonSummary of WorkCommittee Meetings ScheduleBills Referred to CommitteesReports PresentedDigitized ReportsPress ReleaseMembership SearchToday's Committee MeetingsCommittee Subject SelectedDepartment Related-RS Govt. AssurancesSANSAD TVIntranet





HomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions











Download as PDF




Print












PDF/WORD(Hindi)


PDF/WORD




                                    GOVERNMENT OF INDIA
                                





                                    MINISTRY OF
                                    AYURVEDA,YOGA & NATUROPATHY,UNANI,SIDDHA AND HOMEOPATHY (AYUSH)






                                    LOK SABHA
                                





UNSTARRED 


                                    QUESTION NO:
                                

3145






                                    ANSWERED ON: 
                                

06.12.2019






Mission Madhumeha




Sanjay Jaiswal














                        Will the Minister of





AYURVEDA,YOGA & NATUROPATHY,UNANI,SIDDHA AND HOMEOPATHY (AYUSH)


                        be pleased to state:-















Will the Minister of AYURVEDA, YOGA AND NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (AYUSH)   be pleased to state: (a) whether it is a fact that the India has second largest number of diabetic patients in the world and if so, the details thereof; (b) whether “Mission Madhumeha” has been able to address this challenge, if so, the details thereof; and (c) the steps being taken to popularize the “BGR34” anti-diabetes medicine developed by CSIR; (d) whether the said medicine has therapeutic efficacy; and if so, the details thereof?






ANSWER




                                                        ANSWERTHE MINISTER OF STATE (IC) OF THE MINISTRY OF AYURVEDA,YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY(SHRI SHRIPAD YESSO NAIK)(a):  	The diabetic population in the country is close to hitting the alarming mark of 69.9 million by 2025, which denotes that the country is expected to witness an increase of 266%.(b): 	The Central of Research in Ayurveda Sciences (CCRAS), and autonomous body under Ministry of AYUSH has been engaged in extending research oriented Ayurveda based on integrative health care services for the management of Madhumeha which is Diabetes Mellitus. The following are the core activities 1.	CCRAS  in collaboration with Directorate General of Health Services, Ministry of Health & Family Welfare has implemented and executed a programme viz. Integration of AYUSH (Ayurveda) component with NPCDCS(National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular diseases & Stroke ) programme in the identified districts of 3 states viz. Bhilwara (Rajasthan), Surendranagar (Gujarat) and Gaya (Bihar) to cater health care services and to reduce the burden of NCDs including Diabetes by combining the strength of Ayurveda and Yoga. The programme was launched during 2016 and continuing in 3 districts viz. Bhilwara (Rajasthan), Surendranagar (Gujarat) and Gaya (Bihar). The aforesaid programme is now successfully functional in 52 centres (49 CHCs and 3 District Hospitals) of the all 3 identified districts, through AYUSH- NPCDCS Clinic/Lifestyle modification Clinics, established for prevention and management of selected NCDs by Ayurvedic intervention, Lifestyle modifications and Yoga Advice.2.	CCRAS had developed the AYUSH82 formulation for diabetes through scientific process of drug development and commercialized through National Research Development Corporation (NRDC) for wider public utility. 3.	Generation of evidences on efficacy & safety of classical Ayurveda formulation on Diabetes Mellitus. CCRAS has done efficacy and safety on formulations viz. Nishamalki churna, Saptvinsti Gugullu,  Yasad bhasm, Guduchi churna, Chandraprabha vati, Haridra churna anmd Gokshuradi Gugullu.4.	CCRAS has published the documents viz. Protocol on Prevention and Management for Diabetes Mellitus and compendium on research articles on Diabetes Mellitus which are made available in the public domain for benefit of practitioner’s, physician and researchers(c) & (d):   Council of Scientific and Industrial Research (CSIR), through its constituent laboratories namely CSIR-Central Institute of Medicinal & Aromatic Plants (CSIR-CIMAP), Lucknow; and CSIR-National Botanical Research Institute (CSIR-NBRI), Lucknow developed scientifically validated herbal product NBRMAP-DB as anti-diabetic formulation and the knowhow for the product was licensed to M/s AIMIL Pharma Ltd., Delhi who are manufacturing and marketing it as BGR-34, across the country.           M/s AIMIL Pharmaceuticals, the licensee carried out the clinical study of BGR-34 and the trial was registered in clinical trial registry of India (Registration number: CTRI/2016/11/007476). Further, the formulation has shown therapeutic efficacy for treating newly diagnosed type 2 diabetes, as found in independent clinical trials conducted at Banaras Hindu University (BHU), Varanasi.………………….
























HomeArchiveIndex to Select Questions (1984-1999)Ballot ListStatistical Statements Relating to QuestionsUploading of Questions - Status QueryProcedure for Sending Text of Questions & AnswersDemarcation of responsibilities in Govt. of IndiaBrochure on Statutory Corporations, Companies and Other Bodies in Which the Government of India have financial or controlling interestHighlights pertaining to questions of 17th Lok Sabha






Contact Us 
Disclaimer











        Developed and Hosted by National Informatics Centre (NIC)

Content on this website is published,
            managed & maintained by Software Unit, Computer (HW & SW) Management. Branch,
            Lok Sabha Secretariat





HomeMembersBusinessQuestionsDebatesPapers Laid


LegislationCommitteesSANSAD TVIntranetSecretariatPRIDE


RecruitmentSC/ST ReservationConferenceParliament Library


About ParliamentPhoto GalleryRelated LinksRTITendersFAQ


SpeakerDy. SpeakerLeader of the HousePanel of ChairpersonsContact UsFeedback


Council of MinistersPublications of MinistriesParliamentry ProceduresJournal of Parliamentary Information
Visitor's Counter:113163741







Copyright
Privacy Policy
Disclaimer
Terms &
                Conditions

                Accessibility Statement
Accessibility
                Options
Feedback
Site Map







